Clinical Trial Details

USOR 18233

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Gastrointestinal Cancer
Study Type: Interventional
Phase: I
Study Start Date: 02/06/2019
Study Completion Date: 07/2021

This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).

 

NCT Number

NCT03720678

Principal Investigator(s)

John Wallmark, MD

Sponsor(s)

Arcus Biosciences, Inc.

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female